PAVmed Shares Surge After Subsidiary Secures Medicare Coverage for Flagship Test
PAVmed Inc. stock jumped over 21% following news that its main subsidiary, Lucid Diagnostics, received nationwide Medicare reimbursement for its EsoGuard test. The medical device firm reported a Q3 non-GAAP adjusted loss of $1.2 million while advancing regulatory pathways across its technology portfolio.
🧠AI AnalysisPhoto: Motley Fool
Key points
- Lucid Diagnostics secured nationwide Medicare claim reimbursement for its EsoGuard test, driving record test volume in October.
- PAVmed reported a Q3 non-GAAP adjusted loss of $1.2 million while its stock rose 21.73% on the operational milestone.
- The company is preparing an FDA submission for Veris Health's implantable monitor targeted for early 2027.
PAVmed Inc. shares rose 21.73% following its third-quarter business update, propelled by news that its primary subsidiary, Lucid Diagnostics, secured nationwide Medicare reimbursement for its EsoGuard diagnostic test. The company reported a non-GAAP adjusted loss of $1.2 million for the period, while its GAAP net loss reflected non-cash mark-to-market adjustments on its Lucid holdings. For healthcare investors, obtaining federal coverage represents a major commercial threshold that clears the path for broader adoption and standard reimbursement.
Commercial Expansion and Device Pipeline
Lucid Diagnostics began submitting claims through its laboratory in Texas during late September and has received consistent payments at the full Medicare rate since October. Following the reimbursement decision, the firm redirected its commercial efforts toward Medicare-eligible patients, yielding a record month for test volume in October. Management plans to expand its commercial sales infrastructure to meet demand across the country.
Alongside its esophageal diagnostic business, PAVmed is progressing four main technology divisions:
- Lucid Diagnostics: Scaling commercial distribution of the EsoGuard test following nationwide Medicare claim approvals.
- Veris Health: Partnering with Ohio State University to refine clinical workflows ahead of an FDA submission for its implantable oncology monitor in early 2027.
- PortIO & Octeris: Actively engaging with the FDA to advance regulatory pathways for vascular access and imaging devices.
What to watch next: Investors should monitor quarterly test volume figures for EsoGuard to assess commercial momentum, alongside regulatory updates leading up to Veris Health's 2027 FDA filing.
Source Motley Fool — fool.com/earnings/call-transcripts/2026/11/13/pavmed-pavm-q3-2026-e… ↗
Read next
🌍World BusinessBitcoin Technical Analysis Points to Potential Bearish Continuation Setup
Cryptocurrency analysts outline a potential bearish continuation setup for Bitcoin, contingent on a specific price recovery and subsequent rejection at resistance levels.
Los Angeles Developer Lists $30 Million Mansion, Open to Anthropic and OpenAI Stock
A Los Angeles real estate developer has listed a nearly $30 million modern mansion in Brentwood while offering to accept private equity in top artificial intelligence sta…
🧠AI AnalysisBitcoin Tests Support Following Drop Below $60,000 Milestone
Bitcoin recently swept the $55,000 mark before rebounding toward the $59,100 region following a sharp decline that broke previous support levels on November 20.
🧠AI AnalysisEvaluating HF Sinclair and the Turning Oil Refining Cycle
HF Sinclair has experienced impressive expansion driven largely by its refining sector, but market observers suggest the cyclical peak may be near.
🧠AI AnalysisBitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce
Bitcoin remains constrained by a broader bearish pattern on short-term charts as dynamic trendline resistance caps recovery attempts. Although price recently rebounded fr…
🧠AI AnalysisMapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises
A breakdown of a $500 allocation into Infleqtion and Xanadu reveals the high-risk, high-reward nature of early-stage quantum computing investments.